Our study demonstrated that prior to any treatment, the CRC patients had higher plasma levels of total MVs, TF-positive MVs, MUC-1-positive MVs, and EMVs than the controls (p < 0.001). The gene discussed is TF; the disease is colorectal carcinoma.